Last reviewed · How we verify
SOYBEAN OIL
Soybean Oil is a marketed product primarily used in parenteral nutrition, positioning it as a staple component in hospital settings for patients unable to intake nutrients orally. A key strength lies in its broad acceptance and use, underpinned by a key composition patent expiring in 2028, which provides a period of market exclusivity. The primary risk is the potential increase in competition post-patent expiry in 2028, which could erode market share and revenue.
At a glance
| Generic name | SOYBEAN OIL |
|---|---|
| Drug class | Lipid Emulsion [EPC] |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Parenteral Nutrition
- Essential Fatty Acid Deficiency
Common side effects
- Nausea
- Pyrexia
- Hypertension
- Vomiting
- Hemoglobin decreased
- Protein total decreased
- Hypokalemia
- Blood potassium decreased
- Gamma-glutamyltransferase increased
- Hyperglycemia
- Blood alkaline phosphatase increased
- Blood calcium decreased
Serious adverse events
- Parenteral Nutrition-Associated Cholestasis (PNAC)
- Parenteral Nutrition-Associated Liver Disease
- Pulmonary Embolism
- Respiratory Distress due to Pulmonary Vascular Precipitates
- Hypersensitivity Reactions
- Clinical Decompensation with Rapid Infusion
- Infections
Drug interactions
- Coumarin and coumarin derivatives, including warfarin
Key clinical trials
- Heart & Health Study (NA)
- Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH (PHASE2)
- NUTRIBRAIN: Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice (POWER) (NA)
- Reprometabolic Syndrome Mediates Subfertility in Obesity (NA)
- Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression (PHASE2)
- Low Dose Fat-Induced Insulin Resistance (EARLY_PHASE1)
- Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses (PHASE2)
- Omega-3 Supplementation in Systemic Lupus Erythematosus (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |